A Computational Blueprint for Engineering Next-Generation Antibodies
A new computational tool named LICHEN offers a significant advance in antibody engineering by generating viable light-chain immunoglobulin sequences based on a provided heavy-chain sequence. This artificial intelligence model can also incorporate constraints for germline compatibility and specific antigen-binding needs, streamlining the design of therapeutic antibodies. In vitro validation confirms the tool’s utility across various antibody engineering scenarios, potentially accelerating the development of targeted biologics for cancers, autoimmune disorders, and infectious diseases.
Study Significance: For hematologists and oncologists focused on hematologic malignancies like lymphoma and multiple myeloma, this technology could revolutionize the development of bispecific antibodies and CAR-T therapies by optimizing antibody structure and function. It provides a strategic tool for rapidly designing antibodies with improved efficacy and reduced immunogenicity, directly impacting translational research and therapeutic pipeline development in hematology.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
